UCB SA (Germany) Performance
| UNC Stock | EUR 262.00 10.80 4.30% |
On a scale of 0 to 100, UCB SA holds a performance score of 13. The firm owns a Beta (Systematic Risk) of 0.32, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, UCB SA's returns are expected to increase less than the market. However, during the bear market, the loss of holding UCB SA is expected to be smaller as well. Please check UCB SA's downside deviation, total risk alpha, value at risk, as well as the relationship between the information ratio and treynor ratio , to make a quick decision on whether UCB SA's current price history will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in UCB SA are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, UCB SA reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0055 | Payout Ratio 0.2026 | Forward Dividend Rate 1.39 | Ex Dividend Date 2025-04-25 |
1 | UCB Shares Gap Down - Whats Next - MarketBeat | 11/12/2025 |
2 | Barclays Keeps Their Buy Rating on UCB SA - The Globe and Mail | 11/25/2025 |
3 | Analysts Offer Insights on Healthcare Companies Adaptive Biotechnologies , UCB SA and Cibus - The Globe and Mail | 12/30/2025 |
4 | Berenberg Bank Sticks to Their Buy Rating for UCB SA - The Globe and Mail | 01/09/2026 |
UCB |
UCB SA Relative Risk vs. Return Landscape
If you would invest 21,480 in UCB SA on November 6, 2025 and sell it today you would earn a total of 4,720 from holding UCB SA or generate 21.97% return on investment over 90 days. UCB SA is currently producing 0.357% returns and takes up 2.025% volatility of returns over 90 trading days. Put another way, 18% of traded stocks are less volatile than UCB, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
UCB SA Target Price Odds to finish over Current Price
The tendency of UCB Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 262.00 | 90 days | 262.00 | about 5.28 |
Based on a normal probability distribution, the odds of UCB SA to move above the current price in 90 days from now is about 5.28 (This UCB SA probability density function shows the probability of UCB Stock to fall within a particular range of prices over 90 days) .
UCB SA Price Density |
| Price |
Predictive Modules for UCB SA
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as UCB SA. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.UCB SA Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. UCB SA is not an exception. The market had few large corrections towards the UCB SA's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold UCB SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of UCB SA within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 0.32 | |
σ | Overall volatility | 13.20 | |
Ir | Information ratio | 0.05 |
UCB SA Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of UCB SA for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for UCB SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| About 36.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: Berenberg Bank Sticks to Their Buy Rating for UCB SA - The Globe and Mail |
UCB SA Fundamentals Growth
UCB Stock prices reflect investors' perceptions of the future prospects and financial health of UCB SA, and UCB SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on UCB Stock performance.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0463 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 50.38 B | ||||
| Shares Outstanding | 190 M | ||||
| Price To Earning | 25.89 X | ||||
| Price To Book | 4.93 X | ||||
| Price To Sales | 7.27 X | ||||
| Revenue | 6.15 B | ||||
| Gross Profit | 5.02 B | ||||
| EBITDA | 1.85 B | ||||
| Net Income | 1.06 B | ||||
| Cash And Equivalents | 831 M | ||||
| Cash Per Share | 4.40 X | ||||
| Total Debt | 2 M | ||||
| Debt To Equity | 0.27 % | ||||
| Book Value Per Share | 50.96 X | ||||
| Cash Flow From Operations | 1.24 B | ||||
| Earnings Per Share | 6.86 X | ||||
| Total Asset | 17.35 B | ||||
| Retained Earnings | 7.39 B | ||||
About UCB SA Performance
By analyzing UCB SA's fundamental ratios, stakeholders can gain valuable insights into UCB SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if UCB SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if UCB SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company was founded in 1928 and is headquartered in Brussels, Belgium. UCB S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 7600 people.Things to note about UCB SA performance evaluation
Checking the ongoing alerts about UCB SA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for UCB SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 36.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: Berenberg Bank Sticks to Their Buy Rating for UCB SA - The Globe and Mail |
- Analyzing UCB SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether UCB SA's stock is overvalued or undervalued compared to its peers.
- Examining UCB SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating UCB SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of UCB SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of UCB SA's stock. These opinions can provide insight into UCB SA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for UCB Stock analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |